Cardiovascular Systems, Inc. (NASDAQ:CSII) Files An 8-K Other Events

Cardiovascular Systems, Inc. (NASDAQ:CSII) Files An 8-K Other Events

Story continues below

Item 8.01. Other Events.

Stockholder Securities Litigation
As previously disclosed, Cardiovascular Systems, Inc. (the
Company) is party to Shoemaker v. Cardiovascular Systems, Inc. et
al., filed in the United States District Court for the District
of Minnesota (the Court). On March 29, 2017, the Court granted
the Companys Motion to Dismiss the Plaintiffs Class Action
Complaint and dismissed Plaintiffs amended complaint without
prejudice. The Court granted the Plaintiffs request for leave to
amend their complaint, which amended complaint must be filed
within 90 days of the Courts order.
Micro Crown Approval
On March 30, 2017, the Company issued press releases announcing
regulatory approval for the Diamondback 360 Coronary Orbital
Atherectomy System Micro Crown in Japan and the United States.
Copies of the press releases are attached hereto as Exhibit 99.1
and Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits.
Press release dated March 30, 2017 regarding approval
in Japan.
Press release dated March 30, 2017 regarding approval
in the United States.

About Cardiovascular Systems, Inc. (NASDAQ:CSII)

Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

Cardiovascular Systems, Inc. (NASDAQ:CSII) Recent Trading Information

Cardiovascular Systems, Inc. (NASDAQ:CSII) closed its last trading session up +0.71 at 28.98 with 151,938 shares trading hands.

An ad to help with our costs